AR119174A1 - Inhibidores de la replicación del virus de inmunodeficiencia humana - Google Patents
Inhibidores de la replicación del virus de inmunodeficiencia humanaInfo
- Publication number
- AR119174A1 AR119174A1 ARP200101700A ARP200101700A AR119174A1 AR 119174 A1 AR119174 A1 AR 119174A1 AR P200101700 A ARP200101700 A AR P200101700A AR P200101700 A ARP200101700 A AR P200101700A AR 119174 A1 AR119174 A1 AR 119174A1
- Authority
- AR
- Argentina
- Prior art keywords
- immunodeficiency virus
- human immunodeficiency
- virus replication
- replication inhibitors
- inhibitors
- Prior art date
Links
- 241000725303 Human immunodeficiency virus Species 0.000 title abstract 3
- 239000003112 inhibitor Substances 0.000 title 1
- 230000029812 viral genome replication Effects 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- AIDS & HIV (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962863406P | 2019-06-19 | 2019-06-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR119174A1 true AR119174A1 (es) | 2021-12-01 |
Family
ID=71738195
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP200101700A AR119174A1 (es) | 2019-06-19 | 2020-06-17 | Inhibidores de la replicación del virus de inmunodeficiencia humana |
Country Status (33)
| Country | Link |
|---|---|
| US (2) | US12129255B2 (https=) |
| EP (1) | EP3986561B1 (https=) |
| JP (1) | JP7628512B2 (https=) |
| KR (1) | KR102932817B1 (https=) |
| CN (2) | CN114245795B (https=) |
| AR (1) | AR119174A1 (https=) |
| AU (1) | AU2020295793B2 (https=) |
| BR (1) | BR112021025655A2 (https=) |
| CL (1) | CL2021003388A1 (https=) |
| CO (1) | CO2021017479A2 (https=) |
| CR (1) | CR20210664A (https=) |
| DK (1) | DK3986561T3 (https=) |
| ES (1) | ES2974541T3 (https=) |
| FI (1) | FI3986561T3 (https=) |
| HR (1) | HRP20240501T1 (https=) |
| HU (1) | HUE065762T2 (https=) |
| IL (1) | IL288750B2 (https=) |
| LT (1) | LT3986561T (https=) |
| MA (1) | MA56526B1 (https=) |
| MD (1) | MD3986561T2 (https=) |
| MX (1) | MX2021016149A (https=) |
| MY (1) | MY206712A (https=) |
| PE (1) | PE20220510A1 (https=) |
| PH (1) | PH12021553180A1 (https=) |
| PL (1) | PL3986561T3 (https=) |
| PT (1) | PT3986561T (https=) |
| RS (1) | RS65304B1 (https=) |
| SI (1) | SI3986561T1 (https=) |
| SM (1) | SMT202400153T1 (https=) |
| TW (1) | TWI850403B (https=) |
| UA (1) | UA128967C2 (https=) |
| UY (1) | UY38755A (https=) |
| WO (1) | WO2020254985A1 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11541055B2 (en) | 2018-10-24 | 2023-01-03 | VIIV Healthcare UK (No.5) Limited | Inhibitors of human immunodeficiency virus replication |
| BR112021025637A2 (pt) | 2019-06-19 | 2022-02-01 | Nmd Pharma As | Compostos para o tratamento de doenças neuromusculares |
| BR112021025655A2 (pt) | 2019-06-19 | 2022-02-01 | Viiv Healthcare Uk No 5 Ltd | Inibidores da replicação do vírus da imunodeficiência humana |
| MX2022003945A (es) * | 2019-10-01 | 2022-04-25 | Viiv Healthcare Co | Metodo para tratar vih con cabotegravir y rilpivirina. |
| JP7703538B2 (ja) * | 2019-12-09 | 2025-07-07 | ヴィーブ、ヘルスケア、カンパニー | カボテグラビルを含んでなる医薬組成物 |
| KR20220151655A (ko) * | 2020-03-06 | 2022-11-15 | 비브 헬스케어 유케이 (넘버5) 리미티드 | 인간 면역결핍 바이러스 복제의 억제제 |
| BR112022020933A2 (pt) * | 2020-04-15 | 2022-12-06 | Viiv Healthcare Uk No 5 Ltd | Inibidores de replicação do vírus da imunodeficiência humana |
| MX2024004551A (es) * | 2021-10-13 | 2024-06-26 | Viiv Healthcare Uk No 5 Ltd | Inhibidores de la replicacion del virus de inmunodeficiencia humana. |
| US20250042926A1 (en) | 2023-05-31 | 2025-02-06 | Gilead Sciences, Inc. | Therapeutic compounds for hiv |
| CN121335877A (zh) | 2023-06-15 | 2026-01-13 | Viiv保健英国第五有限公司 | 用于制备化合物的方法和中间体 |
| TW202547514A (zh) | 2024-02-05 | 2025-12-16 | 英商Ｖｉｉｖ醫療保健英國(Ｎｏ 5)有限公司 | 人類免疫不全病毒複製之抑制劑 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1363705B9 (en) | 2001-02-02 | 2012-11-07 | Bristol-Myers Squibb Company | Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives |
| US20030207910A1 (en) | 2001-02-02 | 2003-11-06 | Tao Wang | Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives |
| PL2212324T3 (pl) * | 2008-07-02 | 2014-11-28 | Avexa Ltd | Związki posiadające właściwości przeciwwirusowe |
| CN102464654B (zh) | 2010-11-12 | 2016-01-13 | 上海泓博智源医药技术有限公司 | 抗病毒化合物 |
| AU2012278976B2 (en) | 2011-07-06 | 2017-05-11 | Gilead Sciences, Inc. | Compounds for the treatment of HIV |
| CN102863512B (zh) | 2011-07-07 | 2016-04-20 | 上海泓博智源医药技术有限公司 | 抗病毒化合物 |
| ES2642265T3 (es) | 2013-01-09 | 2017-11-16 | Gilead Sciences, Inc. | Compuestos terapéuticos para el tratamiento de infecciones virales |
| US9220710B2 (en) | 2013-01-09 | 2015-12-29 | Gilead Sciences, Inc. | Therapeutic compounds |
| TW201443037A (zh) * | 2013-01-09 | 2014-11-16 | Gilead Sciences Inc | 治療用化合物 |
| TWI694071B (zh) | 2013-03-01 | 2020-05-21 | 美商基利科學股份有限公司 | 治療反轉錄病毒科(Retroviridae)病毒感染之治療性化合物 |
| WO2015130966A1 (en) | 2014-02-28 | 2015-09-03 | Gilead Sciences, Inc. | Antiviral agents |
| US10202353B2 (en) | 2014-02-28 | 2019-02-12 | Gilead Sciences, Inc. | Therapeutic compounds |
| EP3186239B1 (en) | 2014-08-29 | 2018-10-10 | Gilead Sciences, Inc. | Antiretroviral agents |
| CN119462611A (zh) | 2016-08-19 | 2025-02-18 | 吉利德科学公司 | 用于预防性或治疗性治疗hiv病毒感染的治疗性化合物 |
| WO2018045150A1 (en) * | 2016-09-02 | 2018-03-08 | Gilead Sciences, Inc. | 4,6-diamino-pyrido[3,2-d]pyrimidine derivaties as toll like receptor modulators |
| TW201906834A (zh) * | 2017-05-02 | 2019-02-16 | 英商Viiv醫療保健英國(No.5)有限公司 | 人類免疫不全病毒複製之抑制劑 |
| US11541055B2 (en) * | 2018-10-24 | 2023-01-03 | VIIV Healthcare UK (No.5) Limited | Inhibitors of human immunodeficiency virus replication |
| UY38559A (es) * | 2019-02-01 | 2020-07-31 | Viiv Healthcare Uk No 5 Ltd | Inhibidores de la replicación del virus de la inmunodeficiencia humana |
| BR112021025655A2 (pt) | 2019-06-19 | 2022-02-01 | Viiv Healthcare Uk No 5 Ltd | Inibidores da replicação do vírus da imunodeficiência humana |
-
2020
- 2020-06-17 BR BR112021025655A patent/BR112021025655A2/pt unknown
- 2020-06-17 US US17/268,107 patent/US12129255B2/en active Active
- 2020-06-17 TW TW109120334A patent/TWI850403B/zh active
- 2020-06-17 CR CR20210664A patent/CR20210664A/es unknown
- 2020-06-17 PE PE2021002114A patent/PE20220510A1/es unknown
- 2020-06-17 RS RS20240309A patent/RS65304B1/sr unknown
- 2020-06-17 DK DK20743783.1T patent/DK3986561T3/da active
- 2020-06-17 AU AU2020295793A patent/AU2020295793B2/en active Active
- 2020-06-17 IL IL288750A patent/IL288750B2/en unknown
- 2020-06-17 CN CN202080052305.0A patent/CN114245795B/zh active Active
- 2020-06-17 SM SM20240153T patent/SMT202400153T1/it unknown
- 2020-06-17 PH PH1/2021/553180A patent/PH12021553180A1/en unknown
- 2020-06-17 FI FIEP20743783.1T patent/FI3986561T3/fi active
- 2020-06-17 WO PCT/IB2020/055653 patent/WO2020254985A1/en not_active Ceased
- 2020-06-17 PL PL20743783.1T patent/PL3986561T3/pl unknown
- 2020-06-17 HU HUE20743783A patent/HUE065762T2/hu unknown
- 2020-06-17 PT PT207437831T patent/PT3986561T/pt unknown
- 2020-06-17 EP EP20743783.1A patent/EP3986561B1/en active Active
- 2020-06-17 ES ES20743783T patent/ES2974541T3/es active Active
- 2020-06-17 HR HRP20240501TT patent/HRP20240501T1/hr unknown
- 2020-06-17 UA UAA202200207A patent/UA128967C2/uk unknown
- 2020-06-17 MX MX2021016149A patent/MX2021016149A/es unknown
- 2020-06-17 SI SI202030385T patent/SI3986561T1/sl unknown
- 2020-06-17 AR ARP200101700A patent/AR119174A1/es unknown
- 2020-06-17 UY UY0001038755A patent/UY38755A/es unknown
- 2020-06-17 MY MYPI2021007563A patent/MY206712A/en unknown
- 2020-06-17 JP JP2021575482A patent/JP7628512B2/ja active Active
- 2020-06-17 MD MDE20220479T patent/MD3986561T2/ro unknown
- 2020-06-17 LT LTEPPCT/IB2020/055653T patent/LT3986561T/lt unknown
- 2020-06-17 KR KR1020227001501A patent/KR102932817B1/ko active Active
- 2020-06-17 MA MA56526A patent/MA56526B1/fr unknown
- 2020-06-17 CN CN202410979514.XA patent/CN119039288A/zh active Pending
-
2021
- 2021-12-17 CL CL2021003388A patent/CL2021003388A1/es unknown
- 2021-12-20 CO CONC2021/0017479A patent/CO2021017479A2/es unknown
-
2024
- 2024-09-18 US US18/888,497 patent/US20250019383A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR119174A1 (es) | Inhibidores de la replicación del virus de inmunodeficiencia humana | |
| MX2021004593A (es) | Inhibidores de la replicacion del virus de la inmunodeficiencia humana. | |
| UY37710A (es) | Inhibidores de la replicación del virus de la inmunodeficiencia humana | |
| UY38559A (es) | Inhibidores de la replicación del virus de la inmunodeficiencia humana | |
| UY36649A (es) | Inhibidores de la replicación del virus de la inmunodeficiencia humana | |
| CO2020004301A2 (es) | Derivados de 1-benzil-2-imino-4-fenil-5-oxoimidazolidina como inhibidores de la proteasa del vih | |
| BR112022004424A2 (pt) | Pró-fármacos antivirais e formulações dos mesmos | |
| UY36648A (es) | Inhibidores de la replicación del virus de inmunodeficiencia humana | |
| UY35362A (es) | Compuestos terapéuticos | |
| CU24525B1 (es) | Derivado de quinoleína para tratar y prevenir infecciones virales | |
| CL2021002309A1 (es) | Compuestos útiles en la terapia del vih | |
| MX2020009530A (es) | Inhibidores de la o-glicoproteína-2-acetamido-2-desoxi-3-dglicopir anosidasa. | |
| CL2021000329A1 (es) | Compuestos útiles en terapia del vih | |
| MX384729B (es) | Compuestos heterocíclicos tricíclicos útiles como inhibidores de la integrasa del virus de inmunodeficiencia humana (vih). | |
| BR112018002689A2 (pt) | composto, composição útil e método para tratamento de infecção por hiv | |
| CL2022002405A1 (es) | Inhibidores de la replicación del virus de inmunodeficiencia humana | |
| DOP2018000035A (es) | Derivados del ácido 5-(n-bencil-tetrahidroisoquinolin-6-il)-piridin-3-il acético como inhibidores de la replicación del virus de la inmunodeficiencia humana | |
| BR112018015629A2 (pt) | ?composto, composição, método para tratar um mamífero infectado com o vírus hiv, e, proteína mutante tripla? | |
| UY37555A (es) | Derivados de ácido piridin-3-il-acético como inhibidores de la replicación del virus de la inmunodeficiencia humana | |
| ECSP21010874A (es) | Piridopirimidinas como inhibidores del receptor de histamina h4 | |
| MX2025013861A (es) | Compuestos anti virus de la inmunodeficiencia humana (vih) | |
| BR112018002678A2 (pt) | composto, composição, e, método para tratar infecção por hiv | |
| BR112018003181A2 (pt) | composto, composição, e, método para tratar infecção por hiv | |
| BR112018000179A2 (pt) | composto, composição, e, método para tratar a infecção pelo hiv. | |
| BR112018000251A2 (pt) | composto, composição, e, método para tratar a infecção pelo hiv. |